Literature DB >> 33767704

TSC1 Affects the Process of Renal Ischemia-Reperfusion Injury by Controlling Macrophage Polarization.

Xiao Hu1,2, Yanan Xu2,3, Zhaoqi Zhang2,3, Zuofu Tang1, Jinhua Zhang1, You Luo1, Weiming Deng1, Zhanwen Dong1, Yong Zhao2,3,4, Ning Na1.   

Abstract

Renal ischemia-reperfusion injury (IRI) contributes to acute kidney injury (AKI), increases morbidity and mortality, and is a significant risk factor for chronic kidney disease (CKD). Macrophage infiltration is a common feature after renal IRI, and infiltrating macrophages can be polarized into the following two distinct types: M1 macrophages, i.e., classically activated macrophages, which can not only inhibit infection but also accelerate renal injury, and M2 macrophages, i.e., alternatively activated macrophages, which have a repair phenotype that can promote wound healing and subsequent fibrosis. The role of TSC1, which is a negative regulator of mTOR signaling that regulates macrophage polarization in inflammation-linked diseases, has been well documented, but whether TSC1 contributes to macrophage polarization in the process of IRI is still unknown. Here, by using a mouse model of renal ischemia-reperfusion, we found that myeloid cell-specific TSC1 knockout mice (termed Lyz-TSC1 cKO mice) had higher serum creatinine levels, more severe histological damage, and greater proinflammatory cytokine production than wild-type (WT) mice during the early phase after renal ischemia-reperfusion. Furthermore, the Lyz-TSC1 cKO mice showed attenuated renal fibrosis during the repair phase of IRI with decreased levels of M2 markers on macrophages in the operated kidneys, which was further confirmed in a cell model of hypoxia-reoxygenation (H/R) in vitro. Mechanistically, by using RNA sequencing of sorted renal macrophages, we found that the expression of most M1-related genes was upregulated in the Lyz-TSC1 cKO group (Supplemental Table 1) during the early phase. However, C/EBPβ and CD206 expression was decreased during the repair phase compared to in the WT group. Overall, our findings demonstrate that the expression of TSC1 in macrophages contributes to the whole process of IRI but serves as an inflammation suppressor during the early phase and a fibrosis promoter during the repair phase.
Copyright © 2021 Hu, Xu, Zhang, Tang, Zhang, Luo, Deng, Dong, Zhao and Na.

Entities:  

Keywords:  fibrosis; ischemia-reperfusion (IR); kidney; macrophage polarization; tuberous sclerosis complex 1 (TSC1)

Year:  2021        PMID: 33767704      PMCID: PMC7985265          DOI: 10.3389/fimmu.2021.637335

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  56 in total

1.  Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice.

Authors:  D K Kaul; R P Hebbel
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Distinct macrophage phenotypes contribute to kidney injury and repair.

Authors:  Sik Lee; Sarah Huen; Hitoshi Nishio; Saori Nishio; Heung Kyu Lee; Bum-Soon Choi; Christiana Ruhrberg; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2011-02       Impact factor: 10.121

Review 3.  Macrophages in Tissue Repair, Regeneration, and Fibrosis.

Authors:  Thomas A Wynn; Kevin M Vannella
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

Review 4.  Renal tubule injury: a driving force toward chronic kidney disease.

Authors:  Bi-Cheng Liu; Tao-Tao Tang; Lin-Li Lv; Hui-Yao Lan
Journal:  Kidney Int       Date:  2018-01-17       Impact factor: 10.612

5.  An experimental model for assessment of renal recovery from warm ischemia.

Authors:  P Jablonski; B O Howden; D A Rae; C S Birrell; V C Marshall; J Tange
Journal:  Transplantation       Date:  1983-03       Impact factor: 4.939

6.  Anti-B7-1 blocks mononuclear cell adherence in vasa recta after ischemia.

Authors:  K E De Greef; D K Ysebaert; S Dauwe; V Persy; S R Vercauteren; D Mey; M E De Broe
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

7.  Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown.

Authors:  Mihaela Pertea; Daehwan Kim; Geo M Pertea; Jeffrey T Leek; Steven L Salzberg
Journal:  Nat Protoc       Date:  2016-08-11       Impact factor: 13.491

Review 8.  Cellular and molecular mechanisms in kidney fibrosis.

Authors:  Jeremy S Duffield
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

9.  Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway.

Authors:  Daniel Shegogue; Maria Trojanowska
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

Review 10.  The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis.

Authors:  Emily H Steen; Xinyi Wang; Swathi Balaji; Manish J Butte; Paul L Bollyky; Sundeep G Keswani
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-02-07       Impact factor: 4.947

View more
  3 in total

1.  Identification of Subtypes and a Delayed Graft Function Predictive Signature Based on Ferroptosis in Renal Ischemia-Reperfusion Injury.

Authors:  Xiangling Wei; Weiming Deng; Zhanwen Dong; Zhenwei Xie; Jinhua Zhang; Ruojiao Wang; Rui Zhang; Ning Na; Yu Zhou
Journal:  Front Cell Dev Biol       Date:  2022-02-08

2.  Functional consequence of myeloid ferritin heavy chain on acute and chronic effects of rhabdomyolysis-induced kidney injury.

Authors:  Kayla R McCullough; Juheb Akhter; Mauhaun J Taheri; Amie Traylor; Anna A Zmijewska; Vivek Verma; Matthew C Hudson; Abhishek Sachdeva; Elise N Erman; Kyle H Moore; James F George; Subhashini Bolisetty
Journal:  Front Med (Lausanne)       Date:  2022-09-08

3.  TcpC Inhibits M1 but Promotes M2 Macrophage Polarization via Regulation of the MAPK/NF-κB and Akt/STAT6 Pathways in Urinary Tract Infection.

Authors:  Jiaqi Fang; Qian Ou; Boheng Wu; Sisi Li; Mian Wu; Jialing Qiu; Nuo Cen; Kaixin Hu; Yangfei Che; Yuan Ma; Jianping Pan
Journal:  Cells       Date:  2022-08-28       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.